Versanis – Transforming the treatment landscape for obesity and cardiometabolic diseases
Pipeline – Versanis
Versanis Bio on Twitter: "Welcome to the Versanis Board of Directors, John Maraganore @JMaraganore! John brings decades of proven strategic and operational leadership experience in biotechnology to help Versanis realize the full
Careers – Versanis
Versanis Bio Announces Leadership and Board Appointments as Company Prepares to Initiate Phase 2b Study with Novel Approach to Obesity
Versanis.de - Reviews | Facebook
News – Versanis
Team – Versanis
VERSANIS Trademark of VERSANIS BIO, INC. Serial Number: 90555614 :: Trademarkia Trademarks
Team – Versanis
Versanis Bio - Atlas Venture
Versanis Bio - Crunchbase Company Profile & Funding
Versanis Bio snags $70M for a ditched Novartis muscle drug, with a little help from its old CEO Jimenez | Fierce Biotech
Versanis Bio | LinkedIn
Versanis Presents Data Demonstrating Bimagrumab Treatment Leads to Substantial Fat Mass Loss Coupled with Lean Mass Gain in Diabetic and Non-Diabetic Patients
Versanis' bimagrumab, first-in-class obesity therapy, enters Phase IIb of development - Pharmaceutical Technology
Versanis Bio (@VersanisBio) / Twitter
Versanis – Transforming the treatment landscape for obesity and cardiometabolic diseases
Versanis Bio Company Profile: Financials, Valuation, and Growth | PrivCo
Versanis Bio Logo | citybiz
Versanis.de - Reviews | Facebook
Versanis Bio begins enrolment in BELIEVE study for obesity
About Us – Versanis
Versanis Bio unveils $70M and a Novartis drug ready for Phase 2 test in obesity - MedCity News
